Insights & Perspectives

Filter by














Therapeutic Area / Research

Search Insights:
Showing 1 to 10 of 357
Filter by: Unfiltered

Article | Jan 15, 2019

8 Tipping Points: Pharm Exec’s 2019 Industry Forecast

Read more | | Share

Report | Jan 8, 2019

Health Tech: Putting Consumers at the Center of Healthcare

For decades, a person’s relationship with their own health has been mostly a top-down affair – with physicians, institutions, hospitals and payers firmly in charge of decision-making. Today, however, a seismic shift is well underway, as individual consumers are increasingly taking control. Kantar’s latest report shares our thinking on the impact and opportunities for health tech.

Read more | | Share

Article | Jan 8, 2019

Tech adoption lags across the healthcare spectrum

Read more | | Share

Article | Jan 3, 2019

Affordability is Blocking Worldwide Access to Medication

Read more | | Share

Blog Post | Dec 7, 2018

Profiling South Korean Statin Users Leads to Better Outcomes

To better understand the characteristics of statin users in South Korea, we investigated the prevalence of comorbidities and the burden of healthcare resource utilization using 5 years of Health Insurance Review and Assessment-National Patients Sample (HIRA-NPS) data.

Read more | | Share

Blog Post | Dec 6, 2018

KATHERINE extends Roche / Genentech’s reign in HER2+ breast cancer

Co-authored by Stephanie Hawthorne

Read more | | Share

Blog Post | Dec 4, 2018

MAIA: Another bright star for Darzalex in multiple myeloma

Co-authored by Stephanie Hawthorne

Read more | | Share

Blog Post | Dec 4, 2018

Imbruvica combined with Rituxan Outshines FCR Chemoimmunotherapy in Young, Fit Patients in Front-line CLL

Treatment of CLL just became even more chemo free as Imbruvica in combination with Rituxan was shown to be more effective than FCR, the standard chemoimmunotherapy for young, fit patients without TP53 mutated / del17p high-risk disease.

Read more | | Share

Blog Post | Dec 4, 2018

The Golden Years of AML Therapy: New options for unfit/elderly patients

Monumental advances continue in AML with the latest data from ASH 2018 for the newest approvals in unfit AML.

Read more | | Share

Blog Post | Dec 3, 2018

Dislodging the incumbent: Ninlaro poised for an upset win as post-transplant maintenance in multiple myeloma

Co-authored by Stephanie Amato

Read more | | Share
Page  < 12345678910 >